These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 34473313)

  • 1. Therapeutic Effects of Resveratrol on Nonalcoholic Fatty Liver Disease Through Inflammatory, Oxidative Stress, Metabolic, and Epigenetic Modifications.
    Karimi M; Abiri B; Guest PC; Vafa M
    Methods Mol Biol; 2022; 2343():19-35. PubMed ID: 34473313
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Hepatoprotective Effects of Resveratrol in Non-Alcoholic Fatty Live Disease.
    Tejada S; Capó X; Mascaró CM; Monserrat-Mesquida M; Quetglas-Llabrés MM; Pons A; Tur JA; Sureda A
    Curr Pharm Des; 2021; 27(22):2558-2570. PubMed ID: 32303170
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A Molecular Insight into the Role of Antioxidants in Nonalcoholic Fatty Liver Diseases.
    Ezhilarasan D; Lakshmi T
    Oxid Med Cell Longev; 2022; 2022():9233650. PubMed ID: 35602098
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Resveratrol supplementation improves inflammatory biomarkers in patients with nonalcoholic fatty liver disease.
    Faghihzadeh F; Adibi P; Rafiei R; Hekmatdoost A
    Nutr Res; 2014 Oct; 34(10):837-43. PubMed ID: 25311610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treating hyperuricemia related non-alcoholic fatty liver disease in rats with resveratrol.
    Xu K; Liu S; Zhao X; Zhang X; Fu X; Zhou Y; Xu K; Miao L; Li Z; Li Y; Qiao L; Bao J
    Biomed Pharmacother; 2019 Feb; 110():844-849. PubMed ID: 30557833
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Resveratrol does not benefit patients with nonalcoholic fatty liver disease.
    Chachay VS; Macdonald GA; Martin JH; Whitehead JP; O'Moore-Sullivan TM; Lee P; Franklin M; Klein K; Taylor PJ; Ferguson M; Coombes JS; Thomas GP; Cowin GJ; Kirkpatrick CM; Prins JB; Hickman IJ
    Clin Gastroenterol Hepatol; 2014 Dec; 12(12):2092-103.e1-6. PubMed ID: 24582567
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Targeting the gut microbiota with resveratrol: a demonstration of novel evidence for the management of hepatic steatosis.
    Wang P; Wang J; Li D; Ke W; Chen F; Hu X
    J Nutr Biochem; 2020 Jul; 81():108363. PubMed ID: 32388250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Current Update on Preclinical and Clinical Studies of Resveratrol, a Naturally Occurring Phenolic Compound.
    Samuel VP; Gupta G; Dahiya R; Jain DA; Mishra A; Dua K
    Crit Rev Eukaryot Gene Expr; 2019; 29(6):529-537. PubMed ID: 32422008
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Dietary Polyphenols and Non-Alcoholic Fatty Liver Disease.
    Abenavoli L; Larussa T; Corea A; Procopio AC; Boccuto L; Dallio M; Federico A; Luzza F
    Nutrients; 2021 Feb; 13(2):. PubMed ID: 33546130
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of combined therapy with resveratrol, continuous and interval exercises on apoptosis, oxidative stress, and inflammatory biomarkers in the liver of old rats with non-alcoholic fatty liver disease.
    Hajighasem A; Farzanegi P; Mazaheri Z
    Arch Physiol Biochem; 2019 May; 125(2):142-149. PubMed ID: 29463133
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The effect of adiponectin in the pathogenesis of non-alcoholic fatty liver disease (NAFLD) and the potential role of polyphenols in the modulation of adiponectin signaling.
    Shabalala SC; Dludla PV; Mabasa L; Kappo AP; Basson AK; Pheiffer C; Johnson R
    Biomed Pharmacother; 2020 Nov; 131():110785. PubMed ID: 33152943
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Resveratrol protects against nonalcoholic fatty liver disease by improving lipid metabolism and redox homeostasis via the PPARα pathway.
    Huang Y; Lang H; Chen K; Zhang Y; Gao Y; Ran L; Yi L; Mi M; Zhang Q
    Appl Physiol Nutr Metab; 2020 Mar; 45(3):227-239. PubMed ID: 31173696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study.
    Faghihzadeh F; Adibi P; Hekmatdoost A
    Br J Nutr; 2015 Sep; 114(5):796-803. PubMed ID: 26234526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The therapeutic effects of resveratrol on hepatic steatosis in high-fat diet-induced obese mice by improving oxidative stress, inflammation and lipid-related gene transcriptional expression.
    Cheng K; Song Z; Zhang H; Li S; Wang C; Zhang L; Wang T
    Med Mol Morphol; 2019 Dec; 52(4):187-197. PubMed ID: 30673851
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Plumbagin reduces obesity and nonalcoholic fatty liver disease induced by fructose in rats through regulation of lipid metabolism, inflammation and oxidative stress.
    Pai SA; Munshi RP; Panchal FH; Gaur IS; Mestry SN; Gursahani MS; Juvekar AR
    Biomed Pharmacother; 2019 Mar; 111():686-694. PubMed ID: 30611993
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatocellular Interactions of Potential Nutraceuticals in the Management of Inflammatory NAFLD.
    Ezhilarasan D; Langeswaran K
    Cell Biochem Funct; 2024 Sep; 42(7):e4112. PubMed ID: 39238138
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Resveratrol alleviates non-alcoholic fatty liver disease through epigenetic modification of the Nrf2 signaling pathway.
    Hosseini H; Teimouri M; Shabani M; Koushki M; Babaei Khorzoughi R; Namvarjah F; Izadi P; Meshkani R
    Int J Biochem Cell Biol; 2020 Feb; 119():105667. PubMed ID: 31838177
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Role of vitamin E in nonalcoholic fatty liver disease.
    Nagashimada M; Ota T
    IUBMB Life; 2019 Apr; 71(4):516-522. PubMed ID: 30592129
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease.
    Heebøll S; Kreuzfeldt M; Hamilton-Dutoit S; Kjær Poulsen M; Stødkilde-Jørgensen H; Møller HJ; Jessen N; Thorsen K; Kristina Hellberg Y; Bønløkke Pedersen S; Grønbæk H
    Scand J Gastroenterol; 2016; 51(4):456-64. PubMed ID: 26784973
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.